TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02878824

Intervention type: OTHER
Intervention: Ethnicity
Description: As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek \& Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr \& Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong).

Intervention type: OTHER
Intervention: Ethnicity
Description: As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek \& Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr \& Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong).
Study: NCT01658358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: * dose level I, II 1000mg po daily~* dose level III, IV 1250mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: * dose level I, II 1000mg po daily~* dose level III, IV 1250mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipo-Dox
Description: at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipo-Dox
Description: at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
Study: NCT02878824

Intervention type: OTHER
Intervention: Environment
Description: The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray \& Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.

Intervention type: OTHER
Intervention: Environment
Description: The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray \& Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
Study: NCT04258189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.
Study: NCT02753465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left colic artery
Description: Laparoscopic D3 Lymph Node Dissection with preservation of left colic artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High ligation
Description: Laparoscopic D3 Lymph Node Dissection with ligation above the left colic artery
Study: NCT03200535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EHR gaps
Description: Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EHR gaps
Description: Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EHR gaps
Description: Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk outreach
Description: A bulk letter or email will be sent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk outreach
Description: A bulk letter or email will be sent
Study: NCT04258189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.
Study: NCT03213457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone Acetate
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone Acetate
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Elagolix
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for E2/NETA
Description: Tablets
Study: NCT00295828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pegaptanib Sodium Injection/Panretinal Photocoagulation
Description: Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation (PRP)
Description: Ocular Laser Procedure
Study: NCT03162731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy
Description: Undergo simultaneous integrated boost integrated modulated radiation therapy
Study: NCT04727775

Intervention type: DRUG
Intervention: Remdesivir
Description: Antiviral drugs

Intervention type: DRUG
Intervention: Remdesivir
Description: Antiviral drugs

Intervention type: DRUG
Intervention: Remdesivir
Description: Antiviral drugs
Study: NCT03200535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietician call
Description: Patients will receive a personalized call by a registered dietitian
Study: NCT02115854

Intervention type: OTHER
Intervention: labial biopsy
Study: NCT03647319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
Study: NCT03162731

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volume Modulated Arc Therapy
Description: Undergo volumetric modulated arc therapy
Study: NCT02343133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HemaMax

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03722199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
Description: single intake of capsules with flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
Description: single intake of capsules with flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
Description: single intake of capsules with flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single intake of capsules with a placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single intake of capsules with a placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single intake of capsules with a placebo
Study: NCT02587039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic pre-conditioning
Description: Remote ischemic preconditioning is exposure to a brief period ischemia to an area or limb that is not involved in surgery. This intervention is believed to reduce the incidence of cerebral (brain) ischemia during cardiac surgery.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delirium Assessment
Description: The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delirium Assessment
Description: The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
Study: NCT02834377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment algorithm targeting individual cardiac output
Study: NCT02588937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EntecaBell ODT. 0.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baraclude Tab. 0.5mg
Study: NCT00729599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride
Description: Cetylpyridinium chloride during 21 consecutive days.
Study: NCT03213600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation tDCS
Description: 75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
Study: NCT02412436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate
Description: Depot medroxyprogesterone acetate intramuscular injection
Study: NCT03659721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACAM
Description: Support person

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual
Description: Usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COS-P
Description: Attachment based therapy
Study: NCT03186183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GPS program
Description: GPS is a sexual health promotion and HIV prevention program. It has 4 components: provision of information on HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care in the local community (e.g., referrals to medical, social service, social, mental health, and substance use programs). Among HIV-positive men who have sex with men (MSM) GPS is associated with positive health outcomes including decreased likelihood of condomless anal sex (CAS), particularly CAS with serodiscordant partners. GPS is also associated with decreased fear of being rejected for insisting on condom use and increased condom use self-efficacy.
Study: NCT00392288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: Ciclesonide MDI 40 µg BID over twelve weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: Ciclesonide MDI 80 µg BID over twelve weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI over twelve weeks
Study: NCT02544763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT04145245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
Study: NCT03647319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
Study: NCT02370147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking reduction intervention
Description: Smokers was informed that many harmful effects were proved to be related with smoking, such as cancer, coronary heart disease, respiratory disease and many other health problems, and one out of two smokers will be killed by smoking. Smokers will be advised to reduce smoking consumption for at least half of their total consumption in the next month. Finally, all smokers were warned to keep in mind that the current attempt to reduce smoking is an intermediate step before the complete cessation.
Study: NCT03213600

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation tDCS
Description: 75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
Study: NCT02370147

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and diet advice control
Description: Smokers will be asked to do regular activities for three or four times per week, and to have a healthy and balanced diet, having more fruit and vegetables which are rich in vitamins, high in nutrition yet low in calories. In the whole process, advises will not refer to smoking cessation or smoking reduction.
Study: NCT03019263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutraceutical
Description: Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
Study: NCT03079180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training at 80% 1RM
Description: Detailed in Arms section's

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training at 55% 1RM
Description: Detailed in Arms section's

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training at 55% 1RM
Description: Detailed in Arms section's
Study: NCT01046370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amygdala Retraining Program
Description: Mind-body intervention.
Study: NCT04145245

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levocarnitine
Description: Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
Study: NCT02703623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02079363

Intervention type: OTHER
Intervention: No interventions, this is an observational study

Intervention type: OTHER
Intervention: No interventions, this is an observational study

Intervention type: OTHER
Intervention: No interventions, this is an observational study

Intervention type: OTHER
Intervention: No interventions, this is an observational study
Study: NCT01802216

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: non-surgical periodontal disease treatment
Study: NCT03647319

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
Study: NCT02703623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01802216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: antibiotic microspheres
Study: NCT02703623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study: NCT03868124

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: G2-TR intraocular implant containing travoprost
Description: Provided in Arm/Group descriptions

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: G2-TR intraocular implant containing travoprost
Description: Provided in Arm/Group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham surgery + active-comparator eye drops
Description: Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
Study: NCT04582708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NERv's Inline Device
Description: NERv's Inline Device is comprised of multiple sensors. It attaches in line to existing catheters or peritoneal drains that are currently approved for medical use. This allows the device to measure the pH and electrical conductivity of effluent fluids that are drained through peritoneal drains.
Study: NCT02449616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MST-188
Description: Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
Study: NCT04302337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curettage adenoidectomy with transoral endoscopic ablation
Description: Transoral endoscopic examination of nasopharynx at the end of cold curettage adenoidectomy, and, if found, ablation of residual tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cold curettage adenoidectomy
Description: Conventional cold curettage adenoidectomy without endoscopic examination for residual tissue.
Study: NCT01920750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MLCwA
Description: Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MLCwA
Description: Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MLSA-LAM
Description: Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MLSA-LAM
Description: Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
Study: NCT01920750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mock Antigen
Description: Physiological saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mock Antigen
Description: Physiological saline
Study: NCT01465568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: 60mg subcutaneous injection 6 monthly for 2 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisphosphonates
Description: continue present bisphosphonate treatment